(Q38045797)

27 August 2017

title

Lurasidone in schizophrenia: new information about dosage and place in therapy (English)

1 reference

27 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

20 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

815-825

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-012-0052-6

27 August 2017

exact match

0 references

cites work

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone for schizophrenia: what's different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Using oral ziprasidone effectively: the food effect and dose-response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0052-6

10.1007/S12325-012-0052-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1022489177

0 references

1 reference